In this study, Neonc Technologies Holdings, Inc. showed that the cytotoxicity effects of its patented NEO212 compound Nasopharyngeal carcinoma (NPC) could inhibit NPC cell proliferation, and cause G2/M arrest and DNA damage. NEO212 is Neonc’s patented conjugated formulation of Temozolomide with Neonc’s highly purified Perillyl Alcohol. Temozolomide is a chemotherapy drug used primarily to treat […]

On one of its first studies looking at the effects of intranasal-delivered POH as a therapeutic for cancer, NeOnc Technologies Holdings, Inc. demonstrated that its NEO100 formulation had a marked therapeutic effect on patients with recurrent gliomas. The patients that were studied had become unresponsive to standard cancer therapeutic regimens and faced a dismal prognosis. […]